1
|
Obeticholic Acid
|
REGENERATE; NCT02548351 [21] |
3 |
FXR agonist |
2
|
GS-9674
|
NCT02854605 [23] |
2 |
FXR agonist |
3
|
Elafibranor
|
RESOLVE-IT, NCT02704403 [28] |
3 |
Dual PPAR α/δ agonist |
4
|
Cencriviroc
|
AURORA; NCT03028740 [36,37] |
3 |
CCR2 and CCR5 dual antagonist |
5
|
GR-MD-02
|
NASH-CX [42,43] |
2b |
Galectin-3 inhibitor |
6
|
NGM282
|
NCT02443116 [50] |
2 |
Variant of FGF19 |
7
|
MGL-3196
|
NDT02912260 [53] |
2 |
Selective thyroid hormone receptor-beta agonist |
8
|
Selonsertib
|
STELLAR-3; NCT03053050 [8] and STELLAR-4; NCT03053063 [8] |
3 |
Apoptosis signal-regulating kinase 1 inhibitor |
9
|
Simtuzumab
|
NCT02466516 [62] and NCT01672879 [11] |
2, 2b |
Monoclonal antibody against LOXL2 |
10
|
Selonsertib + Simtuzumab
|
NCT02466516 [62] |
2 |
|
11
|
GS-0976
|
NCT 02856555 [70] |
2 |
Acetyl-coenzyme A carboxylase (ACC) inhibitor |
12
|
Selonsertib + GS-9674
|
ATLAS, NCT03449446 [64] |
2 |
|
13
|
Selonsertib + GS-0976
|
ATLAS, NCT03449446 [64] |
2 |
|
14
|
JKB-121
|
NCT02442687 [71] |
2a |
TLR-4 antagonist |
15
|
SGM-1019
|
NCT |
2a |
Inflammasome inhibitor |
16
|
BMS-986036
|
|
2a |
Pegylated fibroblast growth factor 21 (FGF21) analogue [76,77] |
17
|
Aramchol
|
|
2b |
Synthetic fatty acid/bile acid conjugate [76,77] |
18
|
Volixibet
|
|
2a |
Apical sodium dependent bile acid transporter inhibitor [76,77] |
19
|
LMB763
|
|
2a |
FXR agonist [76,77] |
20
|
LJN452
|
|
2a |
FXR agonist [76,77] |
21
|
Emricasan
|
|
2b |
Oral caspase inhibitor [76,77] |
22
|
Saroglitazar
|
|
2a |
PPAR α/δ agonist [76,77] |
23
|
IVA337
|
|
2a |
Pan-PPAR agonist [76,77] |
24
|
IMM-124E-Hyperimmune bovine colostrum
|
|
2a |
Induction of regulatory T-cells [76,77] |
25
|
BI-1467335
|
|
2a |
Amino-oxidase copper (AOC) containing-3 inhibitor [76,77] |
26
|
LIK066
|
|
2a |
Sodium glucose cotransporter inhibitor (SGLT) [77] |